1. Home
  2. Serious Bacterial Infections
Global Antibiotic Research and Development Partnership

Serious Bacterial Infections

Last updated: 29/10/2021
IATI Identifier: CH-FDJP-CHE331930936-SBI-20
Project disclaimer
Disclaimer: The data for this page has been produced from IATI data published by Global Antibiotic Research and Development Partnership. Please contact them (Show Email Address) if you have any questions about their data.


Serious bacterial infections are a major cause of death in hospitals and healthcare settings. Bacteria can enter the body through wounds and surgery sites, ventilators and catheters, leading to pneumonia, urinary tract, abdominal and bloodstream infections. The Global Antibiotic Research and Development Partnership (GARDP) is working to develop new treatments for these serious bacterial infections, focusing on treatments for drug-resistant bacteria on the World Health Organization’s (WHO) priority pathogens list.


The country, countries or regions that benefit from this Programme.
Global project
Disclaimer: Country borders do not necessarily reflect the UK Government's official position.

Status Implementation

The current stage of the Programme, consistent with the International Aid Transparency Initiative's (IATI) classifications.

Programme Spend

Programme budget and spend to date, as per the amounts loaded in financial system(s), and for which procurement has been finalised.

Participating Organisation(s)

Help with participating organisations
These organisations have received funding disbursements from this IATI activity.
  • Global Antibiotic Research and Development Partnership


Sector groups as a percentage of total Programme budget according to the OECD Development Assistance Committee (DAC) classifications.


A comparison across financial years of forecast budget and spend to date on the Programme.

Download IATI Data for CH-FDJP-CHE331930936-SBI-20

Programme data last updated on 29/10/2021